# Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Source: https://onco.cc/trials/nct00998738/  
OnCo record `nct00998738` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ixabepilone in Breast cancer, run by Mayo Clinic, recorded as terminated on the registry.

## Summary

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer is a phase 3 interventional study registered as NCT00998738 by Mayo Clinic, with 1 participants recorded, started 2009-11 and due to reach its primary completion in 2010-07. Interventions recorded: Calcium Gluconate, Magnesium Sulfate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Ixabepilone. Conditions recorded: Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer.

Linked to the drug Ixabepilone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00998738
- Phase: 3
- Setting: The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
- Sponsor: Mayo Clinic
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT00998738: https://clinicaltrials.gov/study/NCT00998738

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Ixabepilone](https://onco.cc/drugs/ixabepilone/)

---
JSON: https://onco.cc/api/v1/entities/nct00998738.json